Types of Chronic Pain Conditions: Which Are Being Studied With Stem Cell Therapy?

"Chronic pain" is not one condition — it is a label covering mechanically distinct problems, from worn-down cartilage to misfiring nerves, and the stem cell research behind each one is at a very different stage. Some categories, particularly knee osteoarthritis, now have a real body of randomized, placebo-controlled human trial data showing a measurable signal. Others, like chronic low back pain from disc degeneration, have been tested rigorously and the results have been disappointing on the question that matters most — relieving pain better than a placebo. Still others, including fibromyalgia and most forms of neuropathic pain, remain largely preclinical or limited to single small pilot studies. This article walks through the major categories of chronic pain and summarizes, honestly, what the evidence does and does not show for each — including that no stem cell therapy is FDA-approved for any chronic pain condition today.

Osteoarthritis and Joint Pain

This is the category with the strongest human evidence. A 2025 dose-focused meta-analysis pooling six randomized controlled trials (roughly 300 patients across eight treatment arms) found that a single intra-articular injection of mesenchymal stem cells (MSCs) — sourced from fat, bone marrow, or umbilical cord tissue — produced a moderate-to-large improvement in WOMAC scores (which combine pain, stiffness, and function) at 12 months compared with controls. Seven of eight treatment arms showed statistically significant benefit, and doses of 25 million cells or fewer performed as well as or better than higher doses. The authors rated the overall certainty of evidence as low to moderate — real signal, but not yet definitive, and more and larger trials are needed before this becomes standard, FDA-sanctioned care.

Degenerative Disc Disease and Chronic Low Back Pain

This category illustrates why rigorous trials matter. The RESPINE study, a multicenter, randomized, placebo-controlled trial published in Annals of the Rheumatic Diseases (2024), tested a single intradiscal injection of allogeneic bone marrow-derived MSCs in 114 patients with chronic low back pain. The result: no meaningful difference from placebo. At 12 months, 74% of the MSC group met the responder criteria for pain and disability improvement versus 69% of the placebo group — not a statistically significant gap. The procedure was safe, with no related serious adverse events, but the trial did not demonstrate efficacy. This is an important, honest data point: a well-designed study of a real stem cell product for this specific condition came back negative on its primary endpoint.

Tendinopathy

Early but genuinely encouraging. A phase IIa proof-of-concept study of autologous bone marrow-derived MSCs in 10 patients with chronic Achilles tendinopathy (published in Scientific Reports, 2024) reported no serious adverse events over 24 weeks and a notable pain improvement: mean MOXFQ pain scores dropped from 52 to 24, with 8 of 10 patients exceeding the threshold for a clinically meaningful change. This is a real, promising signal — but the study was small, uncontrolled, and explicitly designed only to test safety, not to prove efficacy. The authors themselves called for a larger randomized trial before any conclusions about effectiveness can be drawn.

Neuropathic Pain (Including Diabetic Peripheral Neuropathy)

Mostly preclinical. Research into a specially engineered, anti-inflammatory MSC population (dubbed "MSC2") showed meaningful improvement in nerve-related symptoms in diabetic mice — around 40% improvement versus roughly 14% for conventional MSCs — a finding from Tulane University researchers that generated genuine scientific interest. But this work, and most of the broader neuropathic pain literature, remains in animal models. A handful of early human pilot studies are recruiting, but there is not yet meaningful published human efficacy data for neuropathic pain as a category.

Fibromyalgia

The evidence here is thin. A single early-phase pilot trial (registered on ClinicalTrials.gov) has examined adipose-derived stem/stromal cells across a small group of conditions including reflex sympathetic dystrophy, complex regional pain syndrome, and fibromyalgia together — a design that itself reflects how exploratory this work still is. Beyond that, fibromyalgia has essentially no dedicated, adequately powered clinical trial program behind stem cell therapy. Claims of stem cell "treatment" for fibromyalgia marketed outside research settings should be treated with significant skepticism.

Complex Regional Pain Syndrome (CRPS)

Also early-stage, but with a notable research investment behind it. In December 2022, a research institution announced a $5.5 million NIH grant — described as the first federally funded project of its kind — to develop a human mesenchymal stem cell therapy for CRPS, with collaborators at a university and another research institution. As of that announcement, the work was still preclinical: researchers were manufacturing clinical-grade cells and designing a delivery method in animal models, with human trials to follow only after that groundwork is complete. The rationale — that CRPS involves dysregulated neuroimmune signaling that immune-modulating MSCs might address — is scientifically reasonable, but no clinical trial results exist yet.

Bottom Line

The honest picture is uneven. Knee osteoarthritis has the most substantial human trial evidence, with a real (if still low-to-moderate certainty) signal for pain and function improvement. Tendinopathy has small but genuinely promising early safety and pain data. Chronic low back pain from disc degeneration has been tested rigorously and, so far, has not beaten placebo. Neuropathic pain, fibromyalgia, and CRPS remain largely preclinical or limited to pilot-scale research, with real scientific rationale but no robust human efficacy data yet. Across every one of these categories, no stem cell therapy is FDA-approved for any chronic pain indication — the FDA states plainly that no stem cell or exosome product has been approved for any orthopedic condition or for chronic pain generally, and warns that some products marketed for these uses may carry real safety risks. Anyone considering stem cell therapy for chronic pain should understand which category their condition falls into, what phase of research actually supports it, and that "promising early research" is not the same as "proven treatment."